UB Paderborn / Katalog / Suche / in CDI

Sortiert nach

Einfacher Volltextzugriff von (fast) überall

Installieren Sie die LibKey Nomad-Browsererweiterung und erhalten Sie von vielen Webseiten einfachen Zugriff auf lizenzierte Volltexte oder Open Access Publikationen. Mehr erfahren...

RANK ligand and osteoprotegerin in myeloma bone disease

Blood, 2003-03, Vol.101 (6), p.2094-2098

2003

Volltextzugriff (PDF)

Circulating proteasome levels are an independent prognostic factor for survival in multiple myeloma

Blood, 2007-03, Vol.109 (5), p.2100-2105

2007

Volltextzugriff (PDF)

Proteasome inhibitors abrogate osteoclast differentiation and osteoclast function

Biochemical and biophysical research communications, 2005-07, Vol.333 (1), p.200-205

2005

Volltextzugriff (PDF)

Bortezomib increases osteoblast activity in myeloma patients irrespective of response to treatment

European journal of haematology, 2006-09, Vol.77 (3), p.233-238

2006

Volltextzugriff (PDF)

Novel aspects of osteoclast activation and osteoblast inhibition in myeloma bone disease

Biochemical and biophysical research communications, 2005-12, Vol.338 (2), p.687-693

2005

Volltextzugriff (PDF)

Expression of Receptor Activator of Nuclear Factor κB Ligand on Bone Marrow Plasma Cells Correlates with Osteolytic Bone Disease in Patients with Multiple Myeloma

Clinical cancer research, 2003-04, Vol.9 (4), p.1436

2003

Volltextzugriff (PDF)

Proteasome: an emerging target for cancer therapy

Anti-cancer drugs, 2005-06, Vol.16 (5), p.475-481

2005

Volltextzugriff (PDF)

Immunocytochemistry reveals RANKL expression of myeloma cells

Blood, 2002-06, Vol.99 (12), p.4646-4647

2002

Volltextzugriff (PDF)

Serum Levels of Carboxy-terminal Telopeptide of Type-I Collagen Are Elevated in Patients with Multiple Myeloma Showing Skeletal Manifestations in Magnetic Resonance Imaging but Lacking Lytic Bone Lesions in Conventional Radiography

Clinical cancer research, 2003-08, Vol.9 (8), p.3047-3051

2003

Volltextzugriff (PDF)

Molecular and Clinical Aspects of Proteasome Inhibition in the Treatment of Cancer

Recent results in cancer research, 2007, Vol.176, p.165-176

2007

Volltextzugriff (PDF)

Angiogenesis in multiple myeloma

European journal of cancer (1990), 2006-07, Vol.42 (11), p.1581-1590

2006

Volltextzugriff (PDF)

Proteasome inhibitors induce growth inhibition and apoptosis in myeloma cell lines and in human bone marrow myeloma cells irrespective of chromosome 13 deletion

Journal of cancer research and clinical oncology, 2003-07, Vol.129 (7), p.383-391

2003

Volltextzugriff (PDF)

The effects of the histone deacetylase inhibitor valproic acid on cell cycle, growth suppression and apoptosis in multiple myeloma

Haematologica (Roma), 2006-02, Vol.91 (2), p.248-251

2006

Volltextzugriff (PDF)

Bone markers in multiple myeloma

European journal of cancer (1990), 2006-07, Vol.42 (11), p.1544-1553

2006

Volltextzugriff (PDF)

Histone deacetylase inhibitors reduce VEGF production and induce growth suppression and apoptosis in human mantle cell lymphoma

European journal of haematology, 2006-01, Vol.76 (1), p.42-50

2006

Volltextzugriff (PDF)

Proteasome: an emerging target for cancer therapy

Anti-cancer drugs, 2005-06, Vol.16 (5), p.475-481

2005

Volltextzugriff (PDF)

Peroxisome proliferator-activated receptor-gamma ligands inhibit proliferation and induce apoptosis in mantle cell lymphoma

Anti-cancer drugs, 2006-08, Vol.17 (7), p.763-769

2006

Volltextzugriff (PDF)

Differentiation of monoclonal gammopathy of undetermined significance and multiple myeloma using flow cytometric characteristics of plasma cells

Haematologica (Roma), 2001-08, Vol.86 (8), p.837

2001

Volltextzugriff (PDF)

Ligands of peroxisome proliferator-activated receptor γ induce apoptosis in multiple myeloma

Anti-cancer drugs, 2004-11, Vol.15 (10), p.955-960

2004

Volltextzugriff (PDF)

Bone resorption parameters [carboxy-terminal telopeptide of type-I collagen (ICTP), amino-terminal collagen type-I telopeptide (NTx), and deoxypyridinoline (Dpd)] in MGUS and multiple myeloma

European journal of haematology, 2002-07, Vol.69 (1), p.37-42

2002

Volltextzugriff (PDF)

Histone Deacetylase Inhibitors Induce Growth Inhibition, Cell Cycle Arrest and Apoptosis in Mantle Cell Lymphoma and Reduce VEGF Production

Blood, 2005-11, Vol.106 (11), p.4817-4817

2005

Volltextzugriff (PDF)

Bortezomib (PS-341) Sensitizes Multiple Myeloma Cell Lines to Etoposide-Induced Apoptosis

Blood, 2005-11, Vol.106 (11), p.5166-5166

2005

Volltextzugriff (PDF)

Valproic Acid Inihibts Histone Deacetylases and Proliferation and Induces Cell Cycle Arrest and Apoptosis in Multiple Myeloma

Blood, 2005-11, Vol.106 (11), p.5165-5165

2005

Volltextzugriff (PDF)

Identification and clinical relevance of receptor activator of nuclear factor kappaB ligand expression of myeloma cells

Cancer research (Chicago, Ill.), 2004-01, Vol.64 (2), p.773-4; author reply 774-5

2004

Volltextzugriff (PDF)

Synergistic Interaction of the Histone Deacetylase Inhibitor SAHA with the Proteasome Inhibitor Bortezomib in Mantle Cell Lymphoma

Blood, 2006-11, Vol.108 (11), p.2509-2509

2006

Volltextzugriff (PDF)

1 – 25 von 46

Suche als RSS-Feed

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(43)
Mit Volltextzugriff
(43)

Publikationsform

Sprache

Englisch
(46)

Erscheinungsjahr

n.n

Thema

Humans
(27)
Life Sciences & Biomedicine
(25)
Science & Technology
(25)
Multiple Myeloma
(14)
Hematology
(13)
Oncology
(12)
Multiple Myeloma - Pathology
(10)
Biological And Medical Sciences
(9)
Medical Sciences
(9)
Multiple Myeloma - Drug Therapy
(9)
Aged
(8)
Middle Aged
(7)
Adult
(6)
Hematologic And Hematopoietic Diseases
(6)
Leukemias. Malignant Lymphomas. Malignant Reticulosis. Myelofibrosis
(6)
Male
(6)
Rank Ligand
(6)
Receptor Activator Of Nuclear Factor-Kappa B
(6)
Aged, 80 And Over
(5)
Female
(5)

15 weitere anzeigen...

Weniger anzeigen...

Menü

Weitere Dienste

Einstellungen

RANK ligand and osteoprotegerin in myeloma bone disease

Circulating proteasome levels are an independent prognostic factor for survival in multiple myeloma

Proteasome inhibitors abrogate osteoclast differentiation and osteoclast function

Bortezomib increases osteoblast activity in myeloma patients irrespective of response to treatment

Novel aspects of osteoclast activation and osteoblast inhibition in myeloma bone disease

Expression of Receptor Activator of Nuclear Factor κB Ligand on Bone Marrow Plasma Cells Correlates with Osteolytic Bone Disease in Patients with Multiple Myeloma

Proteasome: an emerging target for cancer therapy

Immunocytochemistry reveals RANKL expression of myeloma cells

Serum Levels of Carboxy-terminal Telopeptide of Type-I Collagen Are Elevated in Patients with Multiple Myeloma Showing Skeletal Manifestations in Magnetic Resonance Imaging but Lacking Lytic Bone Lesions in Conventional Radiography

Molecular and Clinical Aspects of Proteasome Inhibition in the Treatment of Cancer

Angiogenesis in multiple myeloma

Proteasome inhibitors induce growth inhibition and apoptosis in myeloma cell lines and in human bone marrow myeloma cells irrespective of chromosome 13 deletion

The effects of the histone deacetylase inhibitor valproic acid on cell cycle, growth suppression and apoptosis in multiple myeloma

Bone markers in multiple myeloma

Histone deacetylase inhibitors reduce VEGF production and induce growth suppression and apoptosis in human mantle cell lymphoma

Proteasome: an emerging target for cancer therapy

Peroxisome proliferator-activated receptor-gamma ligands inhibit proliferation and induce apoptosis in mantle cell lymphoma

Differentiation of monoclonal gammopathy of undetermined significance and multiple myeloma using flow cytometric characteristics of plasma cells

Ligands of peroxisome proliferator-activated receptor γ induce apoptosis in multiple myeloma

Bone resorption parameters [carboxy-terminal telopeptide of type-I collagen (ICTP), amino-terminal collagen type-I telopeptide (NTx), and deoxypyridinoline (Dpd)] in MGUS and multiple myeloma

Histone Deacetylase Inhibitors Induce Growth Inhibition, Cell Cycle Arrest and Apoptosis in Mantle Cell Lymphoma and Reduce VEGF Production

Bortezomib (PS-341) Sensitizes Multiple Myeloma Cell Lines to Etoposide-Induced Apoptosis

Valproic Acid Inihibts Histone Deacetylases and Proliferation and Induces Cell Cycle Arrest and Apoptosis in Multiple Myeloma

Identification and clinical relevance of receptor activator of nuclear factor kappaB ligand expression of myeloma cells

Synergistic Interaction of the Histone Deacetylase Inhibitor SAHA with the Proteasome Inhibitor Bortezomib in Mantle Cell Lymphoma

Suchergebnisse filtern